\
&
Contact us
Published on | 3 years ago
ProgrammesThe results of the evaluation are:
Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs - HORIZON-HLTH-2022-DISEASE-06-02-two-stage
Vaccines 2.0 - developing the next generation of vaccines - HORIZON-HLTH-2022-DISEASE-06-03-two-stage
Development of new effective therapies for rare diseases - HORIZON-HLTH-2022-DISEASE-06-04-two-stage
In accordance with General Annex D of the Work Programme, the evaluation of the first-stage proposals was made looking only at the criteria 'excellence' and 'impact'. The threshold for both individual criteria is 4. The overall threshold applying to the sum of the two individual scores was set at a level that ensures the total requested budget of proposals admitted to stage 2 is as close as possible to three times the available budget, and not less than two and a half times the available budget, and is as follows:
Source: Funding & Tenders Portal (Funding Updates)
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Funded under Horizon Europe (HORIZON-INFRA-2022-TECH-01) and running from 2023 to 2026, the ANERIS project aims to tackle the rapid loss of ocean biodiversity. The project’s main objective is to develop, test and implement the next generation of scientific instrumentation tools and methods for sensing and monitoring marine-life. Another key concept of the project is the introduction of the concept of Operational Marine Biology (OMB) as a biodiversity information system. The project consortium consists of 25 partners from 13 countries. Read more about the project and the contribution of Flemish partner VLIZ in this testimonial.